CADENCE PHARMACEUTICALS INC 4

Accession 0001209191-14-022390

CIK 0001333248operating

Filed

Mar 20, 8:00 PM ET

Accepted

Mar 21, 1:22 PM ET

Size

21.2 KB

Accession

0001209191-14-022390

Form 4

Period: 2014-03-19

SVP, Chief Commercial Officer

Transactions

Disposition to Issuer
stock option (right to buy)
2014-03-19$8.60/sh−100,000$860,000→ 0 total
Exercise: $5.40Exp: 2023-03-13→ common stock (100,000 underlying)
Disposition from Tender
common stock
2014-03-19$14.00/sh−2,000$28,000→ 0 total
Disposition to Issuer
stock option (right to buy)
2014-03-19$3.00/sh−125,000$375,000→ 0 total
Exercise: $11.00Exp: 2019-07-14→ common stock (125,000 underlying)
Disposition to Issuer
stock option (right to buy)
2014-03-19$4.78/sh−8,000$38,240→ 0 total
Exercise: $9.22Exp: 2020-03-25→ common stock (8,000 underlying)
Disposition to Issuer
restricted stock unit
2014-03-19$14.00/sh−100,000$1,400,000→ 0 total
Exercise: $0.00→ common stock (100,000 underlying)
Disposition to Issuer
stock option (right to buy)
2014-03-19$4.78/sh−240,000$1,147,200→ 0 total
Exercise: $9.22Exp: 2020-03-25→ common stock (240,000 underlying)
Disposition to Issuer
stock option (right to buy)
2014-03-19$5.45/sh−80,000$436,000→ 0 total
Exercise: $8.55Exp: 2021-03-16→ common stock (80,000 underlying)
Disposition to Issuer
stock option (right to buy)
2014-03-19$10.49/sh−70,314$737,594→ 0 total
Exercise: $3.51Exp: 2022-03-14→ common stock (70,314 underlying)

Footnotes (2)

[F1]In connection with the merger of Cadence Pharmaceuticals, Inc. ("Cadence") with Madison Merger Sub, Inc. ("Merger Sub") on March 19, 2014, and pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") by and among Cadence, Mallinckrodt plc ("Parent") and Merger Sub, dated February 10, 2014, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (a) the number of shares of common stock of Cadence underlying such option multiplied by (b) the excess, if any, of $14.00 (the "Offer Price") over the exercise price per share of such option.
[F2]Pursuant to the terms of the Merger Agreement, these restricted stock units were converted into a right to receive a cash payment upon vesting equal to the product of the Offer Price, without interest, and the number of shares of Cadence common stock subject to this grant (the "Converted Award"). The Converted Award will vest in accordance with the original vesting schedule of the restricted stock units, subject to accelerated vesting upon the earlier to occur of (a) September 11, 2014 or (b) certain terminations of the reporting person's employment as set forth in the Merger Agreement.

Documents

1 file

CADENCE PHARMACEUTICALS INC

CIK 0001333248

Entity typeoperating